Strategic Forecast for the Anti-Parkinson Drugs Industry: Market Outlook 2025-2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Anti-Parkinson Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size for anti-parkinson drugs has seen significant expansion in the past few years. It is projected to increase from $10.39 billion in 2024 to $10.96 billion in 2025, yielding a compound annual growth rate (CAGR) of 5.5%. This growth during the historic period is due to factors such as the aging population, rising disease incidence, enhanced healthcare infrastructure, and advancements in research.

How Will the Anti-Parkinson Drugs Market Size Evolve and Grow by 2029?
The market size of anti-parkinson drugs is set for robust expansion in the coming years, projected to reach "$13.48 billion by 2029 with a compound annual growth rate (CAGR) of 5.3%. This growth in the projected period can be linked to an increase in awareness, advancements in biotechnology, and the emergence of new markets. The projected period is expected to witness notable trends such as investment in research & development, customized medication, therapies aimed at modifying the disease, re-purposing of drugs, telemedicine & remote monitoring, biosimilars, and collaborations in research.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

What Drivers Are Propelling the Growth of Anti-Parkinson Drugs Market Forward?
The growth of the anti-Parkinson drugs market is likely to be propelled by the rising elderly populace and the escalating prevalence of Parkinson's disease (PD). PD is typically found in individuals who are over 60 years of age. For instance, the World Health Organization, a US-based health agency, indicated in October 2022 that by 2030, one in six people worldwide will be 60 or older and by 2050, the number of people in this age group will double to 2.1 billion. Consequently, the surging number of older adults is a significant factor promoting the expansion of the anti-Parkinson drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

Which Emerging Trends Are Transforming the Anti-Parkinson Drugs Market in 2025?
Leading companies in the anti-Parkinson medication market are channeling their efforts towards the creation of innovative therapeutic solutions such as motor fluctuations and dyskinesia. These strategies aim to improve symptom management and lower side effects. The presence of motor fluctuations and dyskinesia often adds to the complexity of treating Parkinson's disease, impacting patient health. In this vein, in January 2024, U.S. based pharmaceutical firm, AbbVie Inc., introduced a novel remedy named PRODUODOPA. This solution, comprised of foslevodopa/foscarbidopa, is an innovative 24-hour subcutaneous infusion therapy designed specifically for advanced Parkinson's disease patients who experience severe motor fluctuations and dyskinesia that other medications cannot alleviate. The therapy involves seamless administration of levodopa, which could potentially prolong the 'on' duration and enhance control over symptoms.

What Are the Key Segments in the Anti-Parkinson Drugs Market?
The anti-parkinson drugs market covered in this report is segmented -

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:
1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa
2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine
3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone
5) By Anticholinergics: Benztropine, Trihexyphenidyl
6) By Other Drugs: Amantadine, Apomorphine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3462&type=smp

Who Are the Key Players Shaping the Anti-Parkinson Drugs Market's Competitive Landscape?
Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

What Geographic Markets Are Powering Growth in the Anti-Parkinson Drugs Market?
North America was the largest region in the anti-Parkinson drugs market in 2024. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3462

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.